Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Regeneron looks to expand label of Eylea HD early next year
5 months ago
R&D
In surprise move, FDA's No. 2 Bumpus to leave agency at end of 2024
5 months ago
People
FDA+
Pfizer’s message to investors: The ship is steadying in 2025 (even if Washington is turbulent)
5 months ago
Pharma
FDA+
Health tech investing during Trump 2.0
5 months ago
Health Tech
Affimed’s early lung cancer data disappoint; Indapta's $22M round
5 months ago
News Briefing
Chicago’s biotech scene is growing up. What’s fueling it?
5 months ago
Startups
UCB, Novartis say a Phase 2a Parkinson's study failed
5 months ago
R&D
How a duty to spend wisely on worker benefits could loosen PBMs' grip on drug prices
5 months ago
Pharma
In Focus
Teva and Sanofi step on the gas with anti-TL1A in IBD
5 months ago
R&D
FDA rejects J&J’s subcutaneous Rybrevant over manufacturing issues
5 months ago
Pharma
Manufacturing
Merck winds down TIGIT, LAG-3 programs meant to temper Keytruda erosion
5 months ago
R&D
Exclusive: Cell therapy startup Shinobi adds Borges as science chief, Katz as top medical officer
5 months ago
People
Startups
The Trump administration could breathe new life into the food-as-medicine movement
5 months ago
Startups
Health Tech
AstraZeneca is denied full FDA approval of Andexxa following critical advisory meeting
5 months ago
Pharma
FDA+
Viridian readies for Tepezza rivalry with new Phase 3 data in thyroid eye disease
5 months ago
R&D
Pharma
What Trump’s FTC picks mean for biopharma dealmaking and PBMs
5 months ago
Deals
Pharma
HRSA pushes back against another 340B rebate model, this time from Sanofi
5 months ago
Pharma
FDA+
Neurocrine gets FDA go-ahead to treat rare adrenal gland condition
5 months ago
Pharma
FDA+
Edgewise shares spike on Phase 2 success for muscular dystrophy drug
5 months ago
R&D
Checkpoint wins FDA approval of checkpoint inhibitor in advanced skin cancer, seeks partner for launch
5 months ago
Pharma
FDA+
Candid inks three T cell engager deals; PepGen trial put on hold
5 months ago
News Briefing
PureTech declares mid-stage trial win for pulmonary fibrosis drug
5 months ago
R&D
Biohaven’s protein degrader cuts antibodies by 60%
5 months ago
R&D
Novo Nordisk to spend $1.2B for new rare disease drug factory in Denmark
5 months ago
Manufacturing
First page
Previous page
63
64
65
66
67
68
69
Next page
Last page